Drug Profile
Research programme: nuclear receptor modulators - AbbVie
Alternative Names: AGN193198Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Class Small molecules
- Mechanism of Action Cytoplasmic and nuclear receptor modulators; Retinoic acid receptor agonists; Retinoic acid receptor antagonists; Retinoid X receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Neutropenia
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 24 Mar 2008 NRX 4204 has moved into clinical development
- 18 May 2007 Vitae Pharmaceuticals sublicenses rights to this research programme to Quest Group International